Found 299 articles
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the senior management team will present at the following upcoming virtual investor conferences:
Aurinia Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
The Canadian biotech announced the acquisition of two new pipeline assets that align with its focus on autoimmune and kidney-related disease.
Aurinia Pharmaceuticals Inc. announced the addition of two novel assets that will expand the Company’s rare autoimmune and kidney-related disease pipeline.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the executive management team will participate in a fireside chat during the Virtual BTIG Annual Biotech Conference on Tuesday, August 10, 2021 at 2:50 p.m. ET.
Aurinia Reports Second Quarter and Six Months 2021 Financial Results and Recent Operational Highlights
Aurinia Pharmaceuticals Inc. issued its financial results for the second quarter ended June 30, 2021.
Aurinia Pharmaceuticals Inc. announced that it will release its second quarter 2021 financial results on Thursday, August 5, 2021, after the markets close.
Aurinia Pharmaceuticals Inc., a commercial stage biopharmaceutical company advancing therapies for severe autoimmune diseases, announced it will voluntarily delist the common shares of the Company from the Toronto Stock Exchange effective as of the close of trading on July 30, 2021.
Oxford Biomedica plc, a leading gene and cell therapy group, is pleased to announce that Dr. Michael Hayden has been appointed to the Group’s Board as a Non-Executive Director
Aurinia Pharmaceuticals Inc. announced the recipients of five $50,000 grant awards to support implementation patient navigation programs targeted toward disadvantaged populations at most risk of developing SLE and LN.
Aurinia Announces Licensing Partner Otsuka Filed Initial Marketing Authorization Application (MAA) for Voclosporin with the European Medicines Agency (EMA)
Aurinia Pharmaceuticals Inc. announced that the Company’s licensing partner, Otsuka Pharmaceutical Europe Ltd., filed an initial Marketing Authorization Application for voclosporin for the treatment of lupus nephritis to the European Medicines Agency. LN is a complication of the autoimmune disease systemic lupus erythematosus that seriously impacts the kidneys.
Gritstone Announces Management Changes, Including the Appointment of Celia Economides as Chief Financial Officer
Gritstone bio, Inc., a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, announced the appointment of Celia Economides as executive vice president and chief financial officer.
Aurinia Pharmaceuticals Inc. announced the appointment of Dr. Brinda Balakrishnan, M.D., Ph.D., to the Company’s Board of Directors effective June 14, 2021.
Aurinia Pharmaceuticals Inc. is pleased to announce that the eight incumbent directors of the Company were elected at the Company’s annual general meeting held on June 7, 2021.
Aurinia Announces Additional Analysis of its AURORA 1 Phase 3 Study Data Presented at ERA-EDTA 2021 Congress
New examination of AURORA 1 Phase 3 data demonstrates increased renal response rates with LUPKYNIS™ (voclosporin) used in combination with MMF and low-dose steroids in patients with lupus nephritis regardless of target urine protein creatinine ratio (UPCR)
venBio Global Strategic Fund IV will invest primarily in drug companies focused on developing therapies for unmet medical needs.
venBio today announced the closing of venBio Global Strategic Fund IV, LP (“venBio Fund IV”), its fourth life sciences venture capital fund, exceeding its target and closing on approximately $550 million in capital commitments in an oversubscribed fundraise.
Aurinia Pharmaceuticals Inc. announced that members of the executive management team will participate in a fireside chat during the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 11:30 a.m. ET.
Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS™ (voclosporin) in Subjects with Lupus Nephritis
Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS ™ (voclosporin) in Subjects with Lupus Nephritis - Individuals treated with LUPKYNIS sustained meaningful reductions in proteinuria with no change in mean eGFR at 104 weeks of treatment -
Aurinia Pharmaceuticals Inc. announced that members of the executive management team will participate in two upcoming investor conferences